Europe caught in innovation quagmire

Article Abstract:

European has a new plan to counter the worsening competitive position of its biopharmaceutical enterprises. The policy is nominally based on a report submitted by Boston-based international consultancy Charles River Associates (CRA) to European Commission, which showed the number of new drug approvals (NDA) in Europe falling from 27 in 1999 to 17 in 2003.

United States, Europe, Forecasts, trends, outlooks, Market share, Forecasts and trends, Market trend/market analysis, Company market share, Biopharmaceutics, Biopharmaceuticals

---

Sanofi takeover jeopardizes Aventis biotech deals

Article Abstract:

Sanofi-Synthelabo (Paris) took over rival pharmaceutical Aventis (Strasbourg, France) on April 25, 2004. It is felt that this could jeopardize Aventis biotech deals but Sanofi could give biotech companies an opportunity to repartner their collaborations in a beneficial way with its in-house R&D infrastructure and its planning.

France, Aventis S.A., AVE, Sanofi-Sythelabo

---

Antibodies' long revenue stream spurs pharma acquisitions

Article Abstract:

The attributes of antibodies like shorter development period has made them ideal for biotech acquisitions. Pharmaceutical industry is interested in the role of monoclonal antibodies (mAbs) in oncology.

Science & research, Management dynamics, Research, Management, Company business management, Monoclonal antibodies, Oncology

Similar abstracts:

• Abstracts: Cebrowski, Albaugh outline Pentagon procurement needs. United technologies '03 profits up 6 percent; 4th qtr up 9 percent
• Abstracts: ConsumerEs use of written product information. Cognitive diversity and team performance in a complex multiple task environment
• Abstracts: The minimum information required for reporting a molecular interaction experiment (MIMIx). In silico simulation of biological network dynamics
• Abstracts: Ligand selectivity and competition between enzymes in silico. Improving catalytic function by ProSAR-driven enzyme evolution
• Abstracts: Biotech buybacks: good or bad? Beware the biotech barker. Biotech IPOs-flop or pop?

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.